1 |
PUBMED |
Persistent mobility disability after neurotoxic chemotherapy |
Hile ES, Fitzgerald GK, Studenski SA |
2010 |
Estados Unidos |
Estudo de caso |
Manifestações clínicas |
2 |
PUBMED |
BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro |
Parker AR, Petluru PN, Wu M, Zhao M, Kochat H, Hausheer FH |
2010 |
Estados Unidos |
Revisão |
Fisiopatologia |
3 |
PUBMED |
Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat |
Carozzi VA, Chiorazzi A, Canta A, Lapidus RG, Slusher BS, Wozniak KM, Cavaletti G |
2010 |
Itália |
Experimental |
Tratamento |
4 |
CINAHL |
Radio frequency ablation in drug resistant chemotherapy-induced peripheral neuropathy: a case report and review of literature |
Yadav N, Philip FA, Gogia V, Choudhary P, Rana SPS, Mishra S, Bhatnagar B |
2010 |
Índia |
Revisão |
Tratamento |
5 |
PUBMED |
Patient perceptions associated with chemotherapy-induced peripheral neuropathy |
Tofthagen C |
2010 |
Estados Unidos |
Ensaio clínico |
Manifestações clínicas |
6 |
WEB OF SCIENCE |
Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice |
Bruna J, Udina E, Alé A, Vilches JJ, Vynckier A, Monbaliu J, Silverman L, Navarro X |
2010 |
Espanha |
Experimental |
Fisiopatologia |
7 |
PUBMED |
A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA |
Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden JD, Kugler JW, Hoff KL, Reddy PS, Rowland KM, Riepl M, Christensen B, Loprinzi CL |
2010 |
Estados Unidos |
Ensaio clínico |
Tratamento |
8 |
PUBMED |
Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies |
Gutiérreza GG, Serenoa M, Miralles A, Casado-Sáenz E, Gutiérrez-Rivas E |
2010 |
Espanha |
Revisão |
Manifestações clínicas |
9 |
PUBMED |
Animal models of chemotherapy-evoked painful periperal neuropathies |
Authier N, Balayssac D, Marchand F, Ling B, Zangarelli A, Descoeur J, Coudore F, Bourinet E, Eschalier A |
2009 |
França |
Revisão |
Tratamento |
10 |
PUBMED |
Neuropatia inducida por quimioterapia: um problema no resuelto |
Velasco R, Bruna J |
2009 |
Espanha |
Revisão |
Manifestações clínicas |
11 |
PUBMED |
Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel |
Reyes-Gibby CC, Morrow PK, Buzdar A, Shete S |
2009 |
Estados Unidos |
Ensaio clínico |
Incidência |
12 |
WEB OF SCIENCE |
Therapy of chemotherapy-induced peripheral neuropathy |
Kaley TJ, DeAngelis LM |
2009 |
Estados Unidos |
Revisão |
Tratamento |
13 |
PUBMED |
Compartmentalized microfluidic culture platform to study mechanism of paclitaxel-induced axonal degeneration |
Yang IH, Siddique R, Hosmane S, Thakor N, Höke A |
2009 |
Estados Unidos |
Experimental |
Fisiopatologia |
14 |
PUBMED |
Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02 |
Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Mukai H, Katsumata N, Sunada Y, Watanabe T, Hausheer FH |
2009 |
Japão |
Ensaio clínico |
Avaliação |
15 |
PUBMED |
Prospective assessment of chemotherapy induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study) |
Kuroi K, Shimozuma K, Ohashi Y, Hisamatsu K, Masuda N, Takeuchi A, Aranishi T, Morita S, Ohsumi S, Hausheer FH |
2009 |
Japão |
Ensaio clínico |
Incidência |
16 |
WEB OF SCIENCE |
The use of cannabinoids (CBs) for the treatment of chemotherapy-induced peripheral neuropathy (CIPN): A retrospective review |
Gingerich J, Wadhwa D, Lemanski L, Krahn M, Daeninck PJ |
2009 |
Canadá |
Revisão |
Tratamento |
17 |
WEB OF SCIENCE |
Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia |
Ramchandren S, Leonard M, Mody RJ, Donohue JE, Moyer J, Hutchinson R, Gurney JG |
2009 |
Estados Unidos |
Ensaio clínico |
Manifestações clínicas |
18 |
PUBMED |
Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy |
Amara S |
2008 |
Estados Unidos |
Revisão |
Tratamento |
19 |
CINAHL |
Chemotherapy-induced peripheral neuropathy was described as background noise affecting daily life |
Alford M |
2008 |
Estados Unidos |
Ensaio clínico |
Manifestações clínicas |
20 |
CINAHL |
Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies |
Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C |
2008 |
Estados Unidos |
Revisão |
Tratamento |
21 |
PUBMED |
Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review |
De Grandis D |
2007 |
Itália |
Revisão |
Tratamento |
22 |
PUBMED |
Vitamin E for the prevention of CIPN: rationale for an ongoing clinical trial |
Kottschade L, Loprinzi C, Rao R |
2007 |
Estados Unidos |
Ensaio clínico |
Tratamento |
23 |
PUBMED |
Putting evidence into practice®: evidence-based interventions for chemotherapy-induced peripheral neuropathy |
Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C |
2007 |
Estados Unidos |
Revisão |
Tratamento |
24 |
PUBMED |
Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF |
Kirchmair R, Tietz AB, Panagiotou E, Walter DH, Silver M, Young-Sup, Yoon Y, Schratzberger P, Weber A, Kusano K, Weinberg DH, Ropper AH, Isner JF, Losordo DW |
2007 |
Estados Unidos |
Ensaio clínico |
Tratamento |
25 |
PUBMED |
Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy |
Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F |
2006 |
Estados Unidos |
Revisão |
Fisiopatologia |
26 |
PUBMED |
Acupuncture treatment of CIPN – a case series |
Wong R, Sagar S |
2006 |
Canadá |
Estudo de caso |
Tratamento |